Home LiteratureArticle Details
PMID: 10553041 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 163 ·No. 10 ·1999-11-15 ·Pages 5211-8

Shimizu J, Yamazaki S, Sakaguchi S

Abstract

This study shows that removal of a T cell subpopulation can evoke effective tumor immunity in otherwise nonresponding animals. Elimination of CD25-expressing T cells, which constitute 5-10% of peripheral CD4+ T cells in normal naive mice, elicited potent immune responses to syngeneic tumors in vivo and eradicated them. The responses were mediated by tumor-specific CD8+ CTLs and tumor-nonspecific CD4-8- cytotoxic cells akin to NK cells. Furthermore, in vitro culture of CD25+4+ T cell-depleted splenic cell suspensions prepared from tumor-unsensitized normal mice led to spontaneous generation of similar CD4-8- cytotoxic cells capable of killing a broad spectrum of tumors; reconstitution of CD25+4+ T cells inhibited the generation. In this culture, self-reactive CD25-4+ T cells responding to self peptides/class II MHC complexes on APCs spontaneously proliferated upon removal of CD25+4+ T cells, secreting large amounts of IL-2. The IL-2 thus produced appeared to be responsible for the generation of CD4-8- NK cells as lymphokine-activated killer cells, because direct addition of an equivalent amount of IL-2 to the culture of CD4-8- cells generated similar lymphokine-activated killer/NK cells, whereas coculture of normal CD4-8- cells with CD25-4+ T cells from IL-2-deficient mice did not. Thus, removal of immunoregulatory CD25+4+ T cells can abrogate immunological unresponsiveness to syngeneic tumors in vivo and in vitro, leading to spontaneous development of tumor-specific effector cells as well as tumor-nonspecific ones. This novel way of evoking tumor immunity would help to devise effective immunotherapy for cancer in humans.

MeSH Terms
Animals Antibodies, Monoclonal/administration & dosage Autoimmune Diseases/immunology CD4 Antigens/biosynthesis Cells, Cultured Immunotherapy, Adoptive/methods Injections, Intravenous Leukemia, Experimental/immunology,therapy Lymphocyte Activation Lymphocyte Depletion Melanoma, Experimental/immunology,therapy Mice Mice, Inbred BALB C Mice, Inbred C3H Mice, Inbred C57BL Mice, Knockout Mice, Nude Mice, SCID Receptors, Interleukin-2/biosynthesis,immunology Sarcoma, Experimental/immunology,therapy Spleen/cytology,immunology T-Lymphocyte Subsets/immunology T-Lymphocytes, Cytotoxic/immunology Tumor Cells, Cultured
Chemicals
Antibodies, Monoclonal CD4 Antigens Receptors, Interleukin-2
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Shimizu J
Department of Immunopathology, Tokyo Metropolitan Institute of Gerontology, Japan.
Yamazaki S
Sakaguchi S
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
1999-11-15
Pages
5211-8
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]